Cwm LLC Buys 2,401 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Cwm LLC boosted its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 21.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,411 shares of the biopharmaceutical company’s stock after buying an additional 2,401 shares during the quarter. Cwm LLC’s holdings in Catalyst Pharmaceuticals were worth $325,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the business. New York State Common Retirement Fund raised its holdings in Catalyst Pharmaceuticals by 155.3% in the 1st quarter. New York State Common Retirement Fund now owns 92,001 shares of the biopharmaceutical company’s stock valued at $2,231,000 after buying an additional 55,968 shares during the last quarter. Cerity Partners LLC raised its holdings in Catalyst Pharmaceuticals by 8.9% in the 1st quarter. Cerity Partners LLC now owns 28,841 shares of the biopharmaceutical company’s stock valued at $699,000 after buying an additional 2,359 shares during the last quarter. Banque Pictet & Cie SA bought a new position in Catalyst Pharmaceuticals in the 1st quarter valued at approximately $561,000. Linden Thomas Advisory Services LLC raised its holdings in Catalyst Pharmaceuticals by 7.9% in the 1st quarter. Linden Thomas Advisory Services LLC now owns 35,233 shares of the biopharmaceutical company’s stock valued at $854,000 after buying an additional 2,594 shares during the last quarter. Finally, Stratos Wealth Advisors LLC bought a new position in Catalyst Pharmaceuticals in the 1st quarter valued at approximately $2,024,000. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $20.97 on Friday. Catalyst Pharmaceuticals, Inc. has a 52-week low of $15.34 and a 52-week high of $26.58. The firm has a 50 day moving average price of $22.96 and a two-hundred day moving average price of $22.89. The firm has a market cap of $2.56 billion, a price-to-earnings ratio of 13.36, a PEG ratio of 0.86 and a beta of 0.66.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 2,324 shares of the firm’s stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $26.41, for a total transaction of $61,376.84. Following the completion of the transaction, the insider owned 42,681 shares in the company, valued at approximately $1,127,205.21. This trade represents a 5.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gary Ingenito sold 200,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $23.68, for a total transaction of $4,736,000.00. Following the transaction, the insider owned 68,873 shares of the company’s stock, valued at approximately $1,630,912.64. The trade was a 74.38% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 247,924 shares of company stock valued at $5,879,369. Company insiders own 10.40% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Thursday, June 5th. Six research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $32.83.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.